美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

NewcelX Ltd.

2.43

+0.01000.41%

盘后：2.34-0.0900-3.70%18:14 EDT

成交量：6,775.00

成交额：1.64万

市值：1,107.69万

市盈率：-0.56

高：2.46

开：2.43

低：2.40

收：2.42

52周最高：30.80

52周最低：1.89

股本：455.84万

流通股本：455.84万

量比：0.82

换手率：0.15%

股息：- -

股息率：- -

每股收益(TTM):-4.3226

每股收益(LYR):-1.7386

净资产收益率：--

总资产收益率：-155.19%

市净率：-0.81

市盈率(LYR):-1.40

数据加载中...

总览公司新闻资讯公告

Newcelx携手Eledon制药推进Ncel-101项目开启1型糖尿病治疗新篇章

Newcelx Ltd.盘中异动早盘急速拉升5.48%

Newcelx Ltd.盘中异动临近收盘股价大涨5.11%报2.78美元

Newcelx Ltd.盘中异动股价大涨6.31%

Newcelx Ltd.盘中异动早盘股价大涨5.93%报2.50美元

Newcelx Ltd.盘中异动早盘股价大涨5.26%报2.60美元

Newcelx Ltd.盘中异动涨7.75% 振幅达22.01%

NewcelX任命瑞士糖尿病创新巨头Julien Boisdron博士加入科学顾问委员会

Newcelx Ltd.盘中异动早盘股价大跌5.14%报2.03美元

NewcelX有限公司通过任命Barrow神经科学研究所首席医疗官Jeremy Shefner博士增强科学顾问委员会

NewcelX 在与 NLS Pharmaceutics Ltd. 合并后提供业务和战略路线图更新

NLS Pharmaceutics：在与Kadimastem合并后，合并公司将继续推进Itol-102项目

NLS Pharmaceutics Ltd. 宣布进行1比10的反向股票拆分并更改名称，以配合与Kadimastem的拟议合并

NLS Pharmaceutics与Kadimastem宣布合并交易的重大前提条件已完成以及Kadimastem股票的退市日期

NLS Pharmaceutics与Kadimastem宣布Kadimastem与Targetgene之间的战略合作，以推动下一代基因编辑细胞疗法

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NCEL/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","market":"US","secType":"STK","nameCN":"NewcelX Ltd.","latestPrice":2.43,"timestamp":1774468800000,"preClose":2.42,"halted":0,"volume":6775,"hourTrading":{"tag":"盘后","latestPrice":2.34,"preClose":2.43,"latestTime":"18:14 EDT","volume":9,"amount":21.860000999999997,"timestamp":1774476880331,"change":-0.09,"changeRate":-0.037037,"amplitude":0.045267},"delay":0,"changeRate":0.004132231404958773,"floatShares":4558400,"shares":4558400,"eps":-4.322621,"marketStatus":"盘后交易","change":0.01,"latestTime":"03-25 19:51:34 EDT","open":2.43,"high":2.4563,"low":2.4,"amount":16448.3009625,"amplitude":0.023264,"askPrice":2.49,"askSize":35,"bidPrice":2.11,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.322621,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774483200000},"marketStatusCode":4,"adr":0,"listingDate":1611896400000,"exchange":"NASDAQ","adjPreClose":2.42,"preHourTrading":{"tag":"盘前","latestPrice":2.372,"preClose":2.46,"latestTime":"08:31 EDT","volume":134,"amount":323.9399884,"timestamp":1774441895576,"change":-0.088,"changeRate":-0.035772,"amplitude":0.060976},"postHourTrading":{"tag":"盘后","latestPrice":2.34,"preClose":2.43,"latestTime":"18:14 EDT","volume":9,"amount":21.860000999999997,"timestamp":1774476880331,"change":-0.09,"changeRate":-0.037037,"amplitude":0.045267},"volumeRatio":0.817782},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","floatShares":4558400,"roa":"-155.19%","roe":"--","lyrEps":-1.738588,"volumeRatio":0.817782,"shares":4558400,"dividePrice":0,"high":2.4563,"amplitude":0.023264,"preClose":2.42,"low":2.4,"week52Low":1.89,"pbRate":"-0.81","week52High":30.799,"institutionHeld":0,"latestPrice":2.43,"committee":0.481481,"eps":-4.322621,"divideRate":0,"volume":6775,"delay":0,"ttmEps":-4.322621,"open":2.43,"prevYearClose":1.9,"prevWeekClose":2.37,"prevMonthClose":2.9,"prevQuarterClose":1.9,"fiveDayClose":2.62,"twentyDayClose":2.88,"sixtyDayClose":2.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-10-31","symbol":"NCEL","defaultRemindTime":1761917400000,"type":"split","dateTimestamp":1761883200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-05-16","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1747368000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-09-27","symbol":"NCEL","defaultRemindTime":1727443800000,"type":"split","dateTimestamp":1727409600000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCEL\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCEL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCEL","date":"2026-03-24","current":-0.563316,"percent":0.864583,"low":-2.085416,"twenty":-0.836919,"median":-0.626448,"eighty":-0.577838,"high":-0.442896,"avg":-0.704039,"sd":0.217642,"marketCap":11168026},"quantilePoints":[{"date":"2025-10-31","current":-2.085416,"twenty":-2.085416,"median":-2.085416,"eighty":-2.085416,"marketCap":39937082.48},{"date":"2025-11-07","current":-0.993097,"twenty":-1.495376,"median":-1.229626,"eighty":-1.098389,"marketCap":18917268},{"date":"2025-11-14","current":-0.808829,"twenty":-1.253274,"median":-0.970727,"eighty":-0.876223,"marketCap":15635236},{"date":"2025-11-21","current":-0.750891,"twenty":-1.145695,"median":-0.878334,"eighty":-0.814355,"marketCap":14358890},{"date":"2025-11-28","current":-0.957951,"twenty":-1.045743,"median":-0.867781,"eighty":-0.806793,"marketCap":18279095},{"date":"2025-12-05","current":-0.856292,"twenty":-0.972009,"median":-0.871696,"eighty":-0.812974,"marketCap":16455744},{"date":"2025-12-12","current":-0.781666,"twenty":-0.995845,"median":-0.875612,"eighty":-0.812974,"marketCap":15179398},{"date":"2025-12-19","current":-0.635834,"twenty":-0.972009,"median":-0.85736,"eighty":-0.781019,"marketCap":12353204},{"date":"2025-12-26","current":-0.613233,"twenty":-0.957493,"median":-0.83848,"eighty":-0.693066,"marketCap":11988534},{"date":"2026-01-02","current":-0.442896,"twenty":-0.955117,"median":-0.833152,"eighty":-0.615876,"marketCap":8660918},{"date":"2026-01-09","current":-0.513637,"twenty":-0.941907,"median":-0.808829,"eighty":-0.589968,"marketCap":10074015},{"date":"2026-01-16","current":-0.561129,"twenty":-0.915578,"median":-0.78535,"eighty":-0.566624,"marketCap":11122442},{"date":"2026-01-23","current":-0.610165,"twenty":-0.913462,"median":-0.76547,"eighty":-0.561129,"marketCap":12125285},{"date":"2026-01-30","current":-0.576613,"twenty":-0.882218,"median":-0.6841,"eighty":-0.565731,"marketCap":11623863},{"date":"2026-02-06","current":-0.601541,"twenty":-0.878334,"median":-0.628521,"eighty":-0.570197,"marketCap":12034117},{"date":"2026-02-13","current":-0.627168,"twenty":-0.875612,"median":-0.627168,"eighty":-0.572325,"marketCap":12717874},{"date":"2026-02-20","current":-0.632256,"twenty":-0.869347,"median":-0.627168,"eighty":-0.573006,"marketCap":12581123},{"date":"2026-02-27","current":-0.656951,"twenty":-0.860299,"median":-0.626808,"eighty":-0.575926,"marketCap":13082544},{"date":"2026-03-06","current":-0.638142,"twenty":-0.856719,"median":-0.630594,"eighty":-0.581513,"marketCap":12854625},{"date":"2026-03-13","current":-0.639458,"twenty":-0.843011,"median":-0.628376,"eighty":-0.587749,"marketCap":12717874},{"date":"2026-03-20","current":-0.559522,"twenty":-0.837754,"median":-0.626853,"eighty":-0.587749,"marketCap":11168026},{"date":"2026-03-24","current":-0.560418,"twenty":-0.836919,"median":-0.626448,"eighty":-0.577838,"marketCap":11168026}],"updateTime":1774466356903},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCEL\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1175524782","title":"Newcelx携手Eledon制药推进Ncel-101项目 开启1型糖尿病治疗新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1175524782","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175524782?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 19:03","pubTimestamp":1773054236,"startTime":"0","endTime":"0","summary":"生物技术公司Newcelx宣布与Eledon制药达成战略合作，双方将共同推进Ncel-101项目在1型糖尿病治疗领域的临床开发。这一合作标志着两家企业在细胞治疗领域的深度协同，有望为自身免疫性疾病患者带来突破性治疗方案。Ncel-101作为Newcelx的核心在研项目，其创新机制针对1型糖尿病的病理基础展开干预。通过整合Eledon制药在免疫调节领域的专有技术平台，该项目有望加速实现从实验室到临床的转化。业界观察人士指出，此次合作或将重塑糖尿病治疗的研发格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2614773552","title":"Newcelx Ltd.盘中异动 早盘急速拉升5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614773552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614773552?lang=zh_cn&edition=fundamental","pubTime":"2026-02-24 22:57","pubTimestamp":1771945028,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日22时57分，Newcelx Ltd.股票出现异动，股价快速拉升5.48%。截至发稿，该股报2.79美元/股，成交量332股，换手率0.01%，振幅0.00%。Newcelx Ltd.股票所在的生物技术行业中，整体涨幅为0.37%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224225708a71a63e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224225708a71a63e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2609517287","title":"Newcelx Ltd.盘中异动 临近收盘股价大涨5.11%报2.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609517287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609517287?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 04:36","pubTimestamp":1770410218,"startTime":"0","endTime":"0","summary":"北京时间2026年02月07日04时36分，Newcelx Ltd.股票出现波动，股价大幅上涨5.11%。截至发稿，该股报2.78美元/股，成交量9751股，换手率0.21%，振幅4.55%。Newcelx Ltd.股票所在的生物技术行业中，整体涨幅为1.43%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207043659a485e10a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207043659a485e10a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2605450954","title":"Newcelx Ltd.盘中异动 股价大涨6.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605450954","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605450954?lang=zh_cn&edition=fundamental","pubTime":"2026-01-23 00:45","pubTimestamp":1769100344,"startTime":"0","endTime":"0","summary":"北京时间2026年01月23日00时45分，Newcelx Ltd.股票出现波动，股价急速拉升6.31%。截至发稿，该股报2.57美元/股，成交量3.0889万股，换手率0.68%，振幅5.37%。Newcelx Ltd.股票所在的生物技术行业中，整体涨幅为0.90%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123004544953df42f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123004544953df42f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"2605787451","title":"Newcelx Ltd.盘中异动 早盘股价大涨5.93%报2.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605787451","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605787451?lang=zh_cn&edition=fundamental","pubTime":"2026-01-21 00:01","pubTimestamp":1768924914,"startTime":"0","endTime":"0","summary":"北京时间2026年01月21日00时01分，Newcelx Ltd.股票出现波动，股价急速上涨5.93%。截至发稿，该股报2.50美元/股，成交量3.5072万股，换手率0.77%，振幅4.66%。Newcelx Ltd.股票所在的生物技术行业中，整体跌幅为0.62%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121000155a7314055&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121000155a7314055&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2603642466","title":"Newcelx Ltd.盘中异动 早盘股价大涨5.26%报2.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603642466","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603642466?lang=zh_cn&edition=fundamental","pubTime":"2026-01-14 23:06","pubTimestamp":1768403216,"startTime":"0","endTime":"0","summary":"北京时间2026年01月14日23时06分，Newcelx Ltd.股票出现波动，股价快速拉升5.26%。截至发稿，该股报2.60美元/股，成交量2.2568万股，换手率0.50%，振幅9.24%。Newcelx Ltd.股票所在的生物技术行业中，整体跌幅为0.16%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011423065697a1d39c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011423065697a1d39c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2601742898","title":"Newcelx Ltd.盘中异动涨7.75% 振幅达22.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601742898","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601742898?lang=zh_cn&edition=fundamental","pubTime":"2026-01-05 22:36","pubTimestamp":1767623778,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时36分，Newcelx Ltd.股票出现波动，股价大幅上涨7.75%。截至发稿，该股报2.25美元/股，成交量47.5385万股，换手率10.43%，振幅22.01%。Newcelx Ltd.股票所在的生物技术行业中，整体跌幅为0.58%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010522361897a10d76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010522361897a10d76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"1122151526","title":"NewcelX任命瑞士糖尿病创新巨头Julien Boisdron博士加入科学顾问委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=1122151526","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122151526?lang=zh_cn&edition=fundamental","pubTime":"2026-01-05 20:07","pubTimestamp":1767614836,"startTime":"0","endTime":"0","summary":"NewcelX Ltd.宣布，瑞士糖尿病创新领域的领军人物Julien Boisdron博士已正式加入其科学顾问委员会。这一重要人事任命将显著增强公司在糖尿病治疗领域的研发实力。Boisdron博士在大型制药企业积累的丰富经验，有望为NewcelX的技术创新和战略发展注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"2595874370","title":"Newcelx Ltd.盘中异动 早盘股价大跌5.14%报2.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595874370","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595874370?lang=zh_cn&edition=fundamental","pubTime":"2025-12-31 00:09","pubTimestamp":1767110949,"startTime":"0","endTime":"0","summary":"北京时间2025年12月31日00时09分，Newcelx Ltd.股票出现异动，股价大幅下跌5.14%。截至发稿，该股报2.03美元/股，成交量2.3783万股，换手率0.52%，振幅3.97%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。Newcelx Ltd.股票所在的生物技术行业中，整体跌幅为0.78%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231000910953bd57a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231000910953bd57a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"1143544598","title":"NewcelX有限公司通过任命Barrow神经科学研究所首席医疗官Jeremy Shefner博士增强科学顾问委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=1143544598","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143544598?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 20:02","pubTimestamp":1763380947,"startTime":"0","endTime":"0","summary":"NewcelX有限公司通过任命Barrow神经科学研究所首席医疗官Jeremy Shefner博士增强科学顾问委员会","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"1199796406","title":"NewcelX 在与 NLS Pharmaceutics Ltd. 合并后提供业务和战略路线图更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1199796406","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199796406?lang=zh_cn&edition=fundamental","pubTime":"2025-11-03 21:27","pubTimestamp":1762176430,"startTime":"0","endTime":"0","summary":"NewcelX 在与 NLS Pharmaceutics Ltd. 合并后提供业务和战略路线图更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"1166589130","title":"NLS Pharmaceutics：在与Kadimastem合并后，合并公司将继续推进Itol-102项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1166589130","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166589130?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 19:22","pubTimestamp":1761736977,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics：在与Kadimastem合并后，合并公司将继续推进Itol-102项目","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4007","NLSP"],"gpt_icon":0},{"id":"1171878787","title":"NLS Pharmaceutics Ltd. 宣布进行1比10的反向股票拆分并更改名称，以配合与Kadimastem的拟议合并","url":"https://stock-news.laohu8.com/highlight/detail?id=1171878787","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171878787?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 18:00","pubTimestamp":1761732022,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics Ltd. 宣布进行1比10的反向股票拆分并更改名称，以配合与Kadimastem的拟议合并。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NCEL","NLSPW","NLSP"],"gpt_icon":0},{"id":"1176769345","title":"NLS Pharmaceutics与Kadimastem宣布合并交易的重大前提条件已完成以及Kadimastem股票的退市日期","url":"https://stock-news.laohu8.com/highlight/detail?id=1176769345","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176769345?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 15:54","pubTimestamp":1761724465,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics与Kadimastem宣布合并交易的重大前提条件已完成，并确认Kadimastem股票的退市日期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NCEL","NLSP"],"gpt_icon":0},{"id":"1131118792","title":"NLS Pharmaceutics与Kadimastem宣布Kadimastem与Targetgene之间的战略合作，以推动下一代基因编辑细胞疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1131118792","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131118792?lang=zh_cn&edition=fundamental","pubTime":"2025-10-27 19:02","pubTimestamp":1761562934,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics与Kadimastem宣布Kadimastem与Targetgene之间的战略合作，以推动下一代基因编辑细胞疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","NLSP","BK4007","NLSPW"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}